10-12 March 2020
The European Medicines Agency (EMA) published an updated Questions and Answers paper on post-authorisation procedurals for users of the centralised procedure. Questions and answers are being updated continuously, and will be marked by “NEW” or “Rev.” with the relevant date upon publication.
The following new or revised questions have been listed (including the corresponding answers) in the integrated version:
2. Type IB variations
2.2. Is the (Co-) Rapporteur involved in Type IB Variations?
2.4. How shall I present and submit my Type IB Variation?
2.5. When shall I submit my Type IB Variation?
2.6. When do I need a linguistic review for changes in the product information? - NEW
2.7. How shall my Type IB variation be handled (timetable)?
2.9. Do I have to submit mock-ups and specimens?
2.10. How should I submit revised product information? In all languages?
2.14. What can be considered an editorial change and how can it be submitted as part of a type IA/IB/II variation?
2.15. Who should I contact if I have a question when preparing my application?
2.16. Who is my contact at the European Medicines Agency during post-authorisation procedures?
3. Type II variations
3.4. How shall I present my Type II Variation application?
3.11. When do I have to submit revised product information? In all languages?
4. Extension applications
4.12. When do I have to submit revised product information? In all languages?
9. Annual Re-assessment
9.3. How shall I present my annual re-assessment application?
10.10. When do I have to submit revised product information? In all languages?
15.2. What is the scope of PSUR assessment under the EU single assessment?
15.3. How shall I present my PSUR and in which format?
15.6. When do changes to the EURD list become legally binding?
15.16. Can I submit a clinical study report together with my PSUR? - NEW
15.17. What are the timelines for the submission of PSURs?
15.18. To whom should I submit my PSUR?
15.19. How will my PSUR submission be handled?
15.20. How shall I submit the Response to a request for Supplementary Information during a PSUSA procedure? - NEW
15.21. How is the CHMP opinion/CMDh position structured and which annexes need to be translated?
15.25. Who should I contact if I have a question regarding the preparation of a PSUR submission before a Procedure Manager is assigned?
15.26. Who should I contact if I have a technical issue with the submission of the PSUR? -NEW
15.27. Who should I contact if I have an issue related to the EURD list? NEW
15.28. Who should I contact if I have an issue related to the payment of fee and QPPV advice notes? NEW
15.29. Who is my contact at the European Medicines Agency during post-authorisation procedures?
On the EMA website you can find the EMA post-authorisation procedural advice for users of the centralised procedure.